An Overview and Interpretation of Important Clinical Studies
on Non-small Cell Lung Cancer in 2021 / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 295-302, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-928812
ABSTRACT
Though the coronavirus disease is still raging in 2021, clinical research on non-small cell lung cancer (NSCLC) did not stop. However, benefiting from advances in lung cancer treatment modality, NSCLC patients have experienced significant improvements in overall survival and quality of life. Currently, research advances on targeted therapy and immunotherapy have together transformed the status of postoperative adjuvant therapy and established a new standard treatment modality for resectable NSCLC. There are equally important research advances in locally advanced and advanced NSCLC, including new treatment modalities, new therapeutic agents, etc., all of which bringing more options for clinical treatment. These therapies will bring changes to NSCLC and will gradually lead to the chronicity of lung cancer in the foreseeable future. Therefore, this paper reviews important studies that will change clinical practice in NSCLC treatment and noteworthy research advances in 2021.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Calidad de Vida
/
Terapia Combinada
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS